Baricitinib en Pacientes con Artritis Reumatoide con Respuesta Inadecuada a Metotrexato: Resultados de un Estudio Fase 3
Clin Exp Rheumatol . Jul-Aug 2020;38(4):732-741. Epub 2020 May 20.This study conducted mainly in Chinese patients with RA, and an inadequate response to MTX, showed that baricitinib 4mg was associated with significant improvements and consistent with the findings from previous clinical trials.The efficacy and safety of baricitinib have been assessed in several clinical trials, predominantly in Caucasian populations. However, evidence on the efficacy and safety of baricitinib in Chinese patients is limited, with only one of the main clinical trial program studi...